News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2025 Caitlin E. Cox December 01, 2025
News Daily News Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People Todd Neale November 22, 2023
News Conference News AHA 2023 Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV Todd Neale November 17, 2023
News Daily News Greater Carotid Plaque Burden in Asthmatic Patients: MESA Michael O'Riordan November 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Daily News Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA Yael L. Maxwell January 27, 2022
News Conference News AHA 2019 EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl Todd Neale November 18, 2019
News Conference News AHA 2019 COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine Caitlin E. Cox November 16, 2019
News Daily News Atherosclerosis Features Differ Among Male Athletes From Different Sports Todd Neale February 18, 2019
News Daily News Serial CTA Shines a Light on Statin Effects in Subclinical CAD Yael L. Maxwell June 15, 2018
News Conference News SCCT 2017 Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See? Yael L. Maxwell July 10, 2017
News Daily News Run to Your Heart’s Content: Marathons Not Linked With Subclinical Atherosclerosis Michael O'Riordan June 09, 2017
News Conference News TCT 2016 COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events Michael O'Riordan November 01, 2016
News Industry News Sudy Indicates PCI Of NIRS-Defined Lipid-Rich Plaque Is Safe And Not Associated With A Greater Incidence Of Adverse Outcomes Compared To PCI of Non Lipid-Rich Plaque November 01, 2016
News Daily News Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT Michael O'Riordan September 29, 2016
News Daily News Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies Michael O'Riordan September 27, 2016
News Daily News CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study Michael O'Riordan September 22, 2016
News Daily News Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV Michael O'Riordan September 20, 2016
News Industry News Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab) September 20, 2016